Empagliflozin containing chitosan-alginate nanoparticles in orodispersible film: preparation, characterization, pharmacokinetic evaluation and its in-vitro anticancer activity

• Published in: Drug development and industrial pharmacy Vol. 48; no. 7; pp. 279 - 291
• Main Authors: Sinha, Suhani, Sonali, Garg, Vandana, Thapa, Sonia, Singh, Shashank, Chauhan, Mahima, Dutt, Rohit, Singh, Rahul Pratap
• Format: Journal Article
• Language: English
• Published: Taylor & Francis 03.07.2022
• Subjects: Anticancer agent; lung cancer; nanomedicine; oral bioavailability; orodispersible film; physicochemical characterization; stability study
• ISSN: 0363-9045; 1520-5762
• DOI: 10.1080/03639045.2022.2108829

The main objective of this study was to develop the orodispersity film containing chitosan-alginate nanoparticles to improve dissolution profile, therapeutic effect with improved bioavailability of empagliflozin through oral route noninvasively for further cytotoxicity study. The nanoparticles were developed through two-step mechanisms ionotropic pre-gelation and polyelectrolyte complexation methods. The prepared nanoparticles were added to a polymer matrix containing hypromellose, polyvinyl alcohol, and maltodextrin and cast to rapidly dissolving thin film by solvent casting method. The physicochemical characteristics of empagliflozin in the orodispersible film were most favorable for further studies. This formulation has achieved a higher permeability (7.2-fold) as compared to the reference drug product (Jardiance) after 45 min. In vivo pharmacokinetic studies in Wistar rats have revealed that chitosan-alginate empagliflozin nanoparticles in the orodispersible film were 1.18-fold more bioavailable in comparison to free empagliflozin in orodispersible film. The C max observed for the empagliflozin-loaded orodispersible film was 15.42 ± 5.13 μg/mL in comparison to 18.21 ± 5.53 μg/mL for empagliflozin nanoparticle-containing orodispersible film and 12.19 ± 6.71 μg/mL for freed rug suspension. The t 1/2 and AUC 0-t values for chitosan-alginate nanoparticles of empagliflozin in the orodispersible film were found1.4-fold more than empagliflozin loaded orodispersible film (without nanoparticles). The cytotoxicity study has shown that chitosan-alginate nanoparticles of empagliflozin in orodispersible film achieved a 2.5-fold higher cytotoxic effect than free empagliflozin in orodispersible film in A549lung cancer cells. This study provides evidence that chitosan-alginate nanoparticles of empagliflozin in orodispersible film can be an effective drug carrier system to improve sustained effect with better bioavailability of poorly water-soluble drug.